logo_red

REAL TALK ON
ALTERNATIVE INVESTMENTS
BUSINESS & FINANCE

The Daily Alpha - 09.29.15

The Daily Alpha - 09.29.15

Garrett Baldwin



Here's Today's Alternative Thinking on All-You-Can-Eat Bread Sticks, Congressional Pitchforks, the Global Oil Rout, Cargill’s Hedge Fund Exit, and Carl Icahn’s American Apocalypse…

“Cost-cutting has been key to the turnaround…”

Starboard Value Partners has revived Olive Garden, turning all-you-can-eat bread sticks into some serious dough. 

The stock has rebounded, and before the Monday selloff in the broader market, shares hovered near $70 per share.

The company has experienced six consecutive quarters of financial growth.

The way that Starboard completed this turnaround is perhaps one of the most unconventional stories of the year. The hedge fund started its efforts in September when it released a 294-slide shaming presentation that criticized the restaurant chain for not salting its pasta water, for placing non-Italian items on its menu, for wasting too much food like breadsticks and pasta sauce.

The frugal presentation and enthusiasm won over investors.

After winning every seat on Darden’s board of directors, Starboard then went to work… literally.

“Every board member worked inside of a restaurant,” Starboard CEO and Darden Chairman Jeff Smith told Bloomberg in June. “Once we went on the board, every single board member took a night and worked inside of a restaurant.”

It was a successful effort to get to know their brand.

“How are we going to be able to make good decisions in the board room without really knowing what’s happening inside the restaurants?” Smith said.

The menu changes worked.

They pushed higher margin items in alcohol.

The stock is up 45% since October 2014.

And its promotions couldn’t be hotter.

Just last week, the firm’s highly-anticipated Never Ending Pasta Pass sold out all online in less than one second. That means the 2,000 people who bought a pass for $100 can receive a dinner portion of pasta with bread sticks, a salad, and unlimited Coca-Cola twice a day for the next seven weeks. All day, every day.

And before anyone says, “Hey, that sounds horrible for you,” keep in mind that these passes sold out in one second and that they are now being resold on the secondary market for up to $899 on eBay.

Starboard realized that Americans love and will pay for exclusivity, unlimited food, and convenience. Some people may think it is nuts to eat at the same restaurant every day, but the man who founded “Body by Chipotle” would disagree.

Repeat customers are the heart and soul of a successful business. As analysts at Sum All explain, “25% to 40% of the total revenues of the most stable businesses in the SumAll network come from returning customers.”

Starboard’s success will probably serve as a Harvard Case Study in the coming years.

“Valeant is using precisely the same business model as Martin Shkreli, the 32-year-old former hedge fund manager whose company recently purchased the life-saving drug Daraprim and increased the price from $13.50 to $750 per pill ‘overnight.”

For Bill Ackman, Monday was a Terrible, Horrible, No Good, Very Bad Day.

On paper, yesterday’s 16.5% plunge in Valeant Pharmaceutical International (VRX) stock likely cost Ackman more than $600 million in one day.

The stock was down another 1.5% today as the moral panic over prescription drugs accelerates.

The stock plunged after Democrats on the House Committee on Oversight and Government Reform asked Chairman Jason Chaffetz, R-Utah, to subpoena the drug company and ask them to testify next week after the firm hiked the prices of two medications it recently purchased.

In the quote above, Maryland Congressman Elijah Cummings accuses Valeant and other drug companies of price gouging. It’s becoming increasingly clear that most Congressmen keep pitchforks over their desks.

Last week, we introduced readers to Martin Shkreli, a hedge fund manager and fan of Chamillionaire lyrics (pictured below on Twitter), who hiked the price of an HIV drug by nearly 5,000% after his company Turing Pharmaceuticals purchased its rights.

Screen shot 20150922 at 11.11.00 am.crop.promo-xlarge2.11.00 am

Since then, Congressional Democrats and Presidential Candidate Hillary Clinton have pushed for pharmaceutical price controls…

Because economics is not their strong suit. (Only 20% of Congressmen have any training in business or economics. Out of Congress’ 535 voting members, just one has a Ph.D. in economics)

There are two outstanding pieces in the last 24 hours on why these price increases are happening in the biotech sector and what Congress’ plan will ultimately lead to down the road.

First, John Graham at Forbes quickly explains that Shkeli exploited poor regulatory oversight and the FDA’s inability to approve generics in a timely fashion. Government has created barriers to entry for competition in the sector… color us all shocked.

Second, here's Megan McArdle over at Bloomberg teaching prescription economics to a person who wants to be the President of the United States and lead the world’s largest economy…

Both are worth your time today.

"We made a really bad call by going overweight energy at the beginning of this year.”

That’s the Chief Equity Strategist of Morgan Stanley throwing in the towel on oil investments. [http://www.bloomberg.com/news/articles/2015-09-28/morgan-stanley-has-given-up-on-energy-stocks]

As noted last week, the global downturn in oil prices is the most important economic story happening on earth right now.

We’re only in the top of the second inning of what could be a wild ride for investors and political leaders around the globe.

“Limited investor demand”

This morning, Cargill said it is walking away from most of its remaining hedge fund business.

The world’s largest agricultural trading shop said it will spin off three hedge fund businesses from its Black River Asset Management to employees.

It’s not chump change either. Black River had $7.4 billion in AUM in June, before it shut down four other hedge funds.

Here’s the Financial Times’ breakdown of Cargill’s decision. 

“I would say it’s an endorsement.”

That’s Carl Icahn’s weighing in on his pick for President: That’s right, Donald Trump.

This morning, Icahn released a five-page policy paper in which he claims the United States is headed for a "bloodbath."

On his website, www.carlicahn.com, the hedge fund manager released a video that raises his concerns about the markets and the direction that the United States is heading in terms of economic inequality.

After watching the video, if you need help coping with the 2016 Presidential race or the direction of the country, here’s an overview of new product launches in alcoholic drinks for the month of August.

That’s all for right now.

Check back tomorrow for more alternative thinking on alternative assets...
















































Fintech

Getting in on the Groundfloor


Dara Albright


















Alternative Thinking on Today's Market Events

The Daily Alpha - 09.21.15


Garrett Baldwin


Assume Breach


Garrett Baldwin


Currencies

The Week Ahead for Forex


FXHQ.com


Alternative Thinking

The Daily Alpha - 09.18.15


Garrett Baldwin


Alternative Thinking on Today's Market Events

The Daily Alpha - 09.17.15


Garrett Baldwin


Alternative Thinking on Today's Market Events

The Daily Alpha - 09.16.15


Garrett Baldwin



Modern Trader

Rise of the Ethical Hacker


Garrett Baldwin





QOTD

Quotes of the Day


Garrett Baldwin



Modern Trader

Why are Hedge Funds Hiring Poker Pros?


Garrett Baldwin


Gambling and Gaming

Wall Street Casino


Garrett Baldwin


Gambling and Gaming

Investing: A Pretentious Word for Gambling?


Doug Litowitz


Gambling and Gaming

Gambling and Gaming: A Common Thread of Risk


Michael Stegemoller, Baylor University


Gambling

Where Gambling Meets Trading


Modern Trader, William Ziemba





Cybersecurity

Fire-sale: Were Three Leading Organizations Hit By A Global Cyber-Attack?


Dr. Timothy Summers and Dr. Joseph Wall


Real Talk

CNBC Demystified


Doug Litowitz


Modern Trader

False prophets


Garrett Baldwin, Illustrated by Mario Zucca


OTC

Why OTC is Back in Vogue


Edward Lopez



Modern Trader Magazine

Does Your Alma Mater?







TAP Innovation Series

Alpha Pages Innovation Series: Acorns


Garrett Baldwin


Alternative Energy

Yield Cos? More like Yield Can’ts!


Bryan Birsic


Vice Spending

April Vice Index Shows Strong Rebound


Andrew Zatlin


Disruptive Technology

Part II: Possible Hedges Against the Robot Apocalypse


Garrett Baldwin


Disruptive Technology

Part I: Possible Hedges Against the Robot Apocalypse


Garrett Baldwin


Water Investment

Rick Rule: Time to Change California’s Water Policy


Global AgInvesting


Insider Trading

Why The Second Circuit Refuses to Reconsider Its Newman Decision


Jonathan N. Halpern, Ehren M. Fournier


Futures Magazine

logo_red

ENTER YOUR EMAIL BELOW TO FOLLOW THE ALPHA PAGES

Art, Antiques & Collectibles • Forestry • Film Investments • Alternative ETFs • Wine, Spirits & Cannabis • Hard Assets • Sports & Exotic Wagering • Oil & Gas Exploration • Startup Investing • Private Equity • Treasure Recovery • Commodities • Digital Currencies • Peer-to-Peer Lending • Venture Capital • Hedge Funds • Private Real Estate • Managed Futures & CTAs • Forex & Derivatives Trading • Alternative Energy • Futures & Options